



Xencor, Inc.
Investor Relations Department
111 West Lemon Avenue
Monrovia, CA 91016
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: XNCR


Last Trade:	21.75
Trade Time:	4:00 PM ET May 25, 2017
Change:	-0.38 (-1.717%)
Day Range	21.65 - 22.35
52-Week Range	12.51 - 29.38
Volume	326,932

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Since Xencor's founding in 1997, investors have been drawn to our remarkable scientific capabilities around monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. Currently, 11 candidates that have been engineered with Xencor's XmAb® technology are in clinical development by us or with partners. Xencor's internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1a development fo... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 11, 2017*
[Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease](#)
- May 9, 2017*
[Xencor Reports First Quarter 2017 Financial Results](#)
- May 2, 2017*
[Xencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017](#)
- Apr 26, 2017*
[Xencor to Present at 42nd Annual Deutsche Bank Health Care Conference](#)
- Apr 17, 2017*
[Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- May 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2016*
[Quarterly Report \(10-Q\)](#)